HC Wainwright Reiterates Buy Rating for OKYO Pharma (NASDAQ:OKYO)

OKYO Pharma (NASDAQ:OKYO)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 455.56% from the company’s current price. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.40) EPS.

OKYO Pharma Trading Up 14.5 %

Shares of NASDAQ:OKYO opened at $1.26 on Thursday. OKYO Pharma has a 52-week low of $0.81 and a 52-week high of $2.12. The firm has a fifty day moving average of $1.05 and a 200 day moving average of $1.24.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.